evipedia.ai
← Back

Salidroside for Health & Longevity

Evidence Review created on 10/10/2026 using AI4L / Opus 5.5

Also known as: Rhodioloside, Rhodosin, p-Tyrosol Glucoside, LANDKIND Pure Salidroside

Motivation

Salidroside, also called rhodioloside, is a natural plant compound concentrated in the roots of golden root, a cold-climate and mountain herb long used to cope with cold, altitude and exhaustion. It is considered one of the main active ingredients behind the herb’s reputation for raising resilience to physical and mental stress, and it is now also sold on its own as a purified supplement made by fermentation.

Interest in the pure compound grew from laboratory and animal work linking it to the cell’s energy-sensing and stress-defense systems, including studies of lifespan in fish, worms and other short-lived animals. The first human trial of the purified, fermentation-made compound focused on exercise capacity, while most human experience still comes from whole-root extracts that contain only small amounts of it.

This review examines purified salidroside for adults pursuing health and longevity: the human, animal and laboratory evidence behind its proposed benefits, its risks and interactions, how it is dosed and monitored, and how the evidence for the pure compound compares with that for whole-root extracts.

Benefits - Risks - Protocol - Conclusion

Four accessible expert and scientific sources that discuss salidroside by name, chosen for depth, relevance to longevity and practical dosing context.

Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io have no content that discusses salidroside in depth: their site searches returned nothing or only brief rhodiola mentions within broader episodes and articles (Rhonda Patrick’s is a short Layne Norton clip that names salidroside once). Only four sources met the depth bar, so the list is not padded.

Grokipedia

Salidroside

AI-written encyclopedia entry covering chemistry, plant sources, biosynthesis, preclinical pharmacology and early exercise trials; useful orientation, though its content is AI-generated rather than written by named experts.

Examine

Salidrosides

Short Examine page introducing salidroside as a Rhodiola rosea compound, with a research feed of study summaries; full analyses require a subscription, and dosing detail sits on Examine’s rhodiola page.

ConsumerLab

No dedicated ConsumerLab article on salidroside exists. The related Rhodiola Rosea Supplements Review reports measured salidroside and rosavin (other rhodiola marker compounds) content of tested rhodiola products (full results for members).

Systematic Reviews

Systematic reviews and meta-analyses of salidroside; all pool only animal or cell studies.

No systematic review or meta-analysis of salidroside’s adverse effects, interactions or long-term safety exists, so the principal risk side of the trade-off is unrepresented.

Mechanism of Action

Salidroside is tyrosol (a simple phenol also in olive oil) bound to glucose. It acts on several stress-response systems rather than one receptor (low selectivity):

  • Energy sensing: activates AMPK (AMP-activated protein kinase, the cell’s fuel gauge), shifting cells toward glucose and fat use (Hu et al., 2021).
  • Mitochondrial renewal: raises SIRT1 (sirtuin 1, an aging-linked regulator enzyme) and PGC-1α (the master switch for new mitochondria), delaying senescence (permanent cell-division arrest) in human fibroblasts (connective-tissue cells) (Mao et al., 2019).
  • Oxygen sensing: modulates HIF-1α (hypoxia-inducible factor 1-alpha, the low-oxygen response switch), promoting vessel growth in bone (Li et al., 2016) yet speeding HIF-1α breakdown in liver-cancer models (Qin et al., 2018).
  • Protein upkeep: binds HSP90 in lifespan models (Zhang et al., 2024).
  • Platelets: reduces platelet activation through AKT/GSK3β (growth-signaling enzymes) in human platelets and mice (Wei et al., 2020).

A competing view holds these effects are hormetic — a mild stressor triggering defenses, lost at high doses (Calabrese et al., 2023).

Pharmacology: no human oral pharmacokinetic study exists. In rats, intravenous salidroside has a half-life of about 1 hour, reaches muscle, fat and gonads more than brain, and is mainly kidney-cleared (Zhang et al., 2013); much is converted to tyrosol (Weng et al., 2026), likely by β-glucosidase (a sugar-cleaving enzyme) (Guo et al., 2014). It neither inhibits nor induces CYP (cytochrome P450, the main liver drug-processing) enzymes in human liver assays (Kasprzyk et al., 2023, authored by the ingredient’s manufacturer; Klaskova et al., 2026, independent).

Historical Context & Evolution

Salidroside takes its name from willow (Salix), from which it was first isolated, but its fame comes from golden root (Rhodiola rosea) and related Rhodiola species. These roots were used in Scandinavian, Russian, Tibetan and Chinese traditional medicine against fatigue, cold and altitude sickness, and Chinese rhodiola tablets, capsules and injections remain approved medicines there (Liang et al., 2024).

Soviet-era research cast rhodiola as an “adaptogen” (a substance said to raise general stress resistance), and Western standardized extracts such as SHR-5 were later tested in small trials, many run with the extract’s developers. Those trials reported less fatigue and better mental performance under stress (Darbinyan et al., 2000), but a systematic review judged the results contradictory and at high or unclear risk of bias (Ishaque et al., 2012). Both sides of that record remain open rather than settled.

Salidroside entered the longevity conversation through animal work: late-life feeding extended lifespan in killifish (Wang et al., 2018) and cell studies linked it to slower cellular aging. Because extracts deliver little salidroside and wild rhodiola is over-harvested, researchers mapped its biosynthetic pathway (Torrens-Spence et al., 2018), enabling fermentation-made pure salidroside. What changed most recently is that this pure compound reached its first human exercise trial (Schwarz et al., 2024), supplied and co-authored by the manufacturer — shifting the question from “does the herb work?” to “does this single molecule work?”

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence for purified salidroside consists of single, small trials from separate groups measuring different outcomes, with no outcome replicated by an independent group.

Medium 🟩 🟩

Heart Protection During Anthracycline Chemotherapy ⭕️ Not Central to Health & Longevity

In a 60-patient randomized, placebo-controlled trial in women with breast cancer, 600 mg/day salidroside started one week before epirubicin (an anthracycline, a heart-toxic chemotherapy class) preserved echocardiographic strain rate (a sensitive ultrasound measure of heart-muscle contraction) at higher cumulative doses (Zhang et al., 2012). Plasma ROS (reactive oxygen species, damaging oxygen molecules) stayed flat with salidroside but rose with placebo. The trial was single-center and short, without heart-failure outcomes. This bears on cancer patients receiving heart-toxic chemotherapy rather than on healthy aging.

Magnitude: Strain-rate peak was 1.67 vs 1.32 per second with placebo at 300 mg/m² cumulative epirubicin, and 1.68 vs 1.40 per second at 400 mg/m² (both p < 0.05, where p (probability) is the chance the difference is random; no 95% CI (confidence interval, the range likely to contain the true effect) reported); no difference at 200 mg/m².

Low 🟩

Exercise Oxygen Uptake ⚠️ Conflicted

Pure salidroside 60 mg/day raised oxygen uptake during interval running versus placebo in one maker-co-authored trial; peak oxygen uptake and endurance did not change (Schwarz et al., 2024). Rhodiola-extract trials (indirect) showed functional gains (Dou et al., 2026; Dou et al., 2026). Net reading: small interval benefit, no peak gain.

Magnitude: Overall oxygen uptake during interval running reached 82.7% of predicted with salidroside vs 79.6% with placebo (Cohen’s d (a standardized effect size) 0.45; no 95% CI reported); peak oxygen uptake did not differ between groups.

Stress, Anxiety and Mental Fatigue ⚠️ Conflicted

Salidroside 20 mg/day, only with L-malic acid, improved perceived stress and anxiety versus placebo in 121 adults left after post-randomization exclusions (Nathan et al., 2026, maker-funded). Developer-linked SHR-5 extract reduced burnout fatigue (Olsson et al., 2009), but rhodiola fatigue trials were contradictory (Ishaque et al., 2012). Net reading: indirect support.

Magnitude: At 20 mg/day salidroside with L-malic acid for 6 weeks, the risk ratio (the chance of the outcome relative to the comparison group) versus placebo was 1.63 (95% CI ± 0.17) for a clinically meaningful drop in perceived stress and 1.51 (95% CI ± 0.18) for anxiety; 25.15% and 20.39% more salidroside than placebo participants, respectively, reached that improvement.

Mild-to-Moderate Depression ⚠️ Conflicted

SHR-5 extract at 340–680 mg/day for 6 weeks improved depression scores versus placebo in a developer-involved trial (Darbinyan et al., 2007), but an independent 12-week US trial found no significant difference (Mao et al., 2015). Both tested whole-root extract, not purified salidroside. Net reading: inconsistent, indirect evidence.

Magnitude: In the 12-week trial, the odds ratio (relative odds of the outcome) for improving versus placebo was 1.39 (95% CI 0.38–5.04); Hamilton depression scores fell 5.1 points with extract (95% CI −8.8 to −1.3) vs 4.6 with placebo (95% CI −8.6 to −0.6), with no significant between-group difference (p = 0.79).

Angina Symptoms in Coronary Heart Disease

Chinese Dazhu Hongjingtian rhodiola preparations added to standard drugs reduced angina (chest pain from poor heart blood flow) attacks in a meta-analysis of 18 trials (Man et al., 2020). These multi-compound extracts are not purified salidroside, and most trials carried high bias risk (Yu et al., 2014).

Magnitude: Weekly angina attacks fell by 1.03 more than with standard drugs alone (95% CI 0.55 to 1.51 fewer); risk ratio 1.57 (95% CI 1.36–1.81) for an 80% or greater drop in attack frequency.

Leg Clots and Blood Flow in Chronic Lung Disease ⭕️ Not Central to Health & Longevity

In 82 patients with COPD (chronic obstructive pulmonary disease) and leg-vein clots, salidroside plus rehabilitation outperformed heparin (an injectable blood thinner) plus rehabilitation on symptoms and blood thickness (Ye et al., 2025). The title calls it rhodiola polyglucoside, so its form is unclear. This bears on lung disease, not aging.

Magnitude: Total effective rate (share of patients rated improved or better) was 95.1% vs 75.6% with low-molecular-weight heparin plus rehabilitation (p = 0.045); no 95% CI reported.

Altitude Sickness Prevention ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Rhodiola crenulata extract raised blood oxygen versus placebo in a 19-trial meta-analysis (Gao et al., 2025), yet did not prevent altitude sickness in a crossover trial (Chiu et al., 2013). Both tested extract, not salidroside; this bears on altitude travel, not aging. Net reading: prevention is unproven.

Magnitude: In the crossover trial of 102 adults ascending to 3,421 m, altitude sickness occurred in 60.8% with extract and 60.8% with placebo (adjusted odds ratio 1.02, 95% CI 0.69–1.52).

Speculative 🟨

Lifespan and Healthspan Extension

Late-life dietary salidroside extended lifespan in killifish (Wang et al., 2018) and in other animal models through HSP90 (Zhang et al., 2024). Basis is animal only; no human aging data exist.

Protection Against Cognitive Decline

A meta-analysis of 20 rodent Alzheimer’s-model studies found better memory and less amyloid (Zhang et al., 2023). Basis is animal only; no human cognition trial of purified salidroside exists.

Liver Fat and Blood Sugar Control

Rodent meta-analyses show less liver fat, lower insulin resistance and fewer kidney-damage markers (Li et al., 2026; Sun et al., 2026). Basis is animal only, with publication-bias warnings.

Ovarian Aging and Fertility

Salidroside restored ovarian blood supply and fertility in middle-aged mice (Mu et al., 2025) and improved egg quality in old mice (Gu et al., 2025). Basis is animal only.

Slower Cellular Senescence

Salidroside delayed senescence of human fibroblasts by boosting SIRT1 and new mitochondria (Mao et al., 2019). Basis is cell culture only; no human tissue-aging outcome has been measured.

Anticancer Activity

A systematic review of 47 cell and animal studies reports antitumor effects across 19 cancer types (Chu et al., 2026). Basis is preclinical only; no human cancer outcome trial exists.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to alter salidroside response; it is mainly cleared by the kidneys and converted to tyrosol, and no CYP-dependent pathway has been shown, so pharmacogenetic testing offers no current guidance.
  • Baseline biomarkers: No baseline marker predicts benefit. Animal metabolic benefits appeared in models with high glucose, liver fat or oxidative stress, suggesting larger effects with elevated fasting glucose or liver enzymes — untested in humans.
  • Sex: The exercise trial lacked sex-specific analysis (Schwarz et al., 2024). In the stress trial, a post hoc (unplanned, after-the-fact) analysis found enhanced benefit in men and non-premenopausal women (Nathan et al., 2026), suggesting hormonal influences.
  • Pre-existing conditions: Human signals come from patients receiving epirubicin and from COPD. In rodents, low oxygen roughly doubled salidroside bioavailability (share reaching the blood) (Weng et al., 2026), so altitude or lung disease may change exposure.
  • Age: Pure-salidroside exercise data come only from adults averaging 21 years. No trial has tested older adults, the group the animal lifespan and cognition rationale targets, whose muscle and vessel responses may differ.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the human safety data are a few small, short trials without any replicated adverse event; remaining signals come from animal toxicology and laboratory assays.

Medium 🟥 🟥

No risk reaches Medium: no human trial or comparative observational study has shown an excess of any adverse event with salidroside or with standardized rhodiola extract versus placebo.

Low 🟥

Mild Tolerability Complaints ⚠️ Conflicted

Rhodiola extracts are linked to dizziness, dry mouth, headache and overstimulation; adverse events were 30.0% vs 16.7% with placebo in one trial (Mao et al., 2015) — extract, not pure compound. Pure salidroside showed no excess (Schwarz et al., 2024). Net reading: low risk.

Magnitude: Pure salidroside at 60 mg/day for 16 days showed no between-group difference across 18 self-reported symptoms (dry mouth was more frequent with placebo); rhodiola extract showed adverse events in 30.0% vs 16.7% with placebo.

Speculative 🟨

Bleeding Tendency

Salidroside reduced human platelet activation in the laboratory and prolonged bleeding time in mice (Wei et al., 2020). Basis is mechanistic and animal only; relevant with anticoagulants (blood thinners) or before surgery.

Unwanted Blood-Vessel Growth

Salidroside activated the HIF-1α–VEGF (vascular endothelial growth factor, a vessel-growth signal) pathway in bone (Li et al., 2016), a tumor or eye-disease concern; tumor studies show suppression (Chu et al., 2026). Basis is preclinical only.

Additive Glucose Lowering

AMPK activation lowered glucose and insulin resistance in rodents (Hu et al., 2021), so additive effects with glucose-lowering drugs are possible. Basis is animal only; no human reports exist.

Unknown Effects in Pregnancy

Manufacturer rat toxicology set a NOAEL (no-observed-adverse-effect level) of 2,000 mg/kg/day (Kasprzyk et al., 2022); a review reports no rat embryo toxicity (Liang et al., 2024). Human pregnancy data are absent; basis is animal only.

Altered Chemotherapy Response

Salidroside changed cancer-cell sensitivity to platinum chemotherapy in laboratory and mouse studies (Qin et al., 2018). Human direction is unknown; basis is preclinical only.

Risk-Modifying Factors

  • Genetic polymorphisms: No known variants alter salidroside clearance, which relies on kidney excretion and conversion to tyrosol. Inherited bleeding disorders (e.g., von Willebrand disease, a clotting-protein deficiency) could amplify the theoretical bleeding risk.
  • Baseline biomarkers: Low platelet count, prolonged clotting times or low fasting glucose raise the theoretical bleeding and low-sugar concerns. Reduced eGFR (estimated glomerular filtration rate, a kidney-function measure) may raise exposure because salidroside is kidney-cleared.
  • Sex: No sex differences in adverse events are reported. Pregnancy and breastfeeding are the main female-specific concerns because human safety data are absent.
  • Pre-existing conditions: Bleeding disorders, cancer under active treatment, medication-treated diabetes and kidney impairment carry the most theoretical risk; bipolar disorder warrants caution with stimulating rhodiola extracts.
  • Age: Older adults more often take anticoagulants, antiplatelets (platelet-blocking drugs) and glucose-lowering drugs and have lower kidney function, magnifying theoretical interactions; no salidroside trial has enrolled older adults.

Key Interactions & Contraindications

Prescription drugs:

  • Anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel): Caution (theoretical) — added platelet inhibition from laboratory and mouse data (Wei et al., 2020) may increase bleeding. Watching for new bruising, nosebleeds or gum bleeding in the first weeks mitigates this.
  • Glucose-lowering drugs (metformin, insulin, insulin-releasing sulfonylureas such as glipizide): Monitor (theoretical) — additive glucose lowering from AMPK activation in animals may cause hypoglycemia (low blood sugar). More frequent glucose checks in the first weeks mitigate this.
  • Blood-pressure-lowering drugs (amlodipine, lisinopril, metoprolol): Monitor (theoretical) — rhodiola extracts may add to blood-pressure lowering through MAO (monoamine oxidase, a mood-chemical-degrading enzyme) inhibition (Memorial Sloan Kettering rhodiola monograph), risking dizziness; pure salidroside left blood pressure unchanged (Schwarz et al., 2024). Home blood-pressure checks mitigate this.
  • Drugs handled by CYP enzymes, MAO or OATP (liver drug-uptake transporters; e.g., atorvastatin): No interaction expected (theoretical) — salidroside spared CYP in liver assays (Klaskova et al., 2026) and CYP, MAO and OATP in manufacturer assays (Kasprzyk et al., 2023).
  • CYP2C9-handled drugs (warfarin, phenytoin, losartan): Monitor with rhodiola extracts — of five drug-clearing liver enzymes, CYP2C9 activity fell 21%, possibly raising drug levels; CYP1A2, CYP2C19, CYP2D6 and CYP3A4 were unaffected (Thu et al., 2016). INR (international normalized ratio, a clotting test) or drug-level checks mitigate this.
  • Drugs moved by P-glycoprotein (a drug-export pump; e.g., digoxin): Caution (theoretical) with whole rhodiola extracts, which inhibited it in laboratory tests (Hellum et al., 2010); drug levels may rise. Digoxin-level checks after starting mitigate this.
  • Antidepressants (SSRIs, selective serotonin reuptake inhibitors, such as sertraline): Caution with whole rhodiola extracts — a combined-use case of rapid irregular heartbeat is reported (Memorial Sloan Kettering rhodiola monograph); purified salidroside showed no MAO inhibition (Kasprzyk et al., 2023). Prescriber review before combining mitigates this.
  • Platinum chemotherapy (cisplatin, oxaliplatin): Caution (theoretical) — salidroside increased platinum-drug sensitivity of liver-cancer cells in laboratory and mouse studies (Qin et al., 2018); effects on human tumor response are unknown. Coordination with the oncology team mitigates this.

Over-the-counter medications:

  • Aspirin and NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen): Caution (theoretical) — combined antiplatelet effects may increase bruising and bleeding, most relevant before surgery or dental procedures. Pausing salidroside 7 days before procedures mitigates this.
  • Caffeine and stimulant pre-workout products: Monitor (theoretical) — rhodiola extracts are mildly stimulating, so combined use may cause jitteriness or insomnia; early-day dosing reduces this.

Supplements:

  • Fish oil, ginkgo, high-dose vitamin E, garlic extract: Caution (theoretical) — additive antiplatelet effects may increase bruising or prolonged bleeding, particularly alongside anticoagulants. Pausing salidroside 7 days before procedures mitigates this.
  • Berberine, chromium, cinnamon extract, alpha-lipoic acid: Monitor (theoretical) — additive glucose lowering may cause hypoglycemia, mainly when combined with diabetes drugs. More frequent glucose checks mitigate this.
  • Rhodiola extracts and adaptogen blends: Monitor (theoretical) — duplicate salidroside intake raises the total dose beyond studied amounts, and extract-specific CYP2C9 inhibition may raise levels of CYP2C9-handled drugs; counting total salidroside across products mitigates this.

Other interventions:

  • High-altitude exposure: Monitor (theoretical) — low oxygen roughly doubled salidroside bioavailability in rodents (Weng et al., 2026), raising exposure; keeping to the studied 60 mg/day limits this.

Populations who should avoid Salidroside:

  • Pregnant or breastfeeding women — no human safety data (theoretical).
  • People under 18 years — the EMA (European Medicines Agency) restricts rhodiola medicines to adults over 18 (EMA rhodiola monograph summary).
  • People with bleeding disorders or awaiting surgery — antiplatelet effect (theoretical).
  • People receiving active chemotherapy, unless coordinated with the oncology team — change in drug sensitivity (theoretical).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Starting at the studied dose: 30 mg twice daily is the only pure-compound regimen tested in healthy adults; single doses up to 180 mg were tolerated (Schwarz et al., 2024); staying there limits mild side effects and high-dose exposure.
  • Pausing before procedures: Stopping salidroside 7 days before surgery or dental extraction reduces the theoretical bleeding risk from platelet inhibition.
  • Watching for bleeding on anticoagulants or antiplatelets: Checking for new bruising, nosebleeds or gum bleeding in the first 2 weeks catches additive antiplatelet bleeding; with rhodiola extracts, an INR check at 1–2 weeks catches CYP2C9-related warfarin rises.
  • Watching glucose with diabetes drugs: Daily fingerstick glucose checks for the first 2 weeks, with low readings or hypoglycemia symptoms reported to the prescriber, guard against hypoglycemia.
  • Verified pure product: Third-party-tested, single-ingredient salidroside with a stated milligram content prevents dosing errors from mislabeled or adulterated rhodiola products (Booker et al., 2016).
  • Early-day dosing: Taking the last dose before mid-afternoon prevents possible insomnia from stimulating effects.
  • Coordination with cancer care: Informing the oncology team before use during chemotherapy prevents unrecognized changes in tumor drug sensitivity.
  • Stopping for pregnancy: Discontinuing when pregnancy is planned or confirmed avoids unknown developmental risk.

Therapeutic Protocol

Doses below are cited to their sources; other parameters (timing, cycling, titration) reflect common practice.

  • Standard pure-compound dose: 60 mg/day as 30 mg twice daily, matching the trial regimen and product labeling (Schwarz et al., 2024); popularized by Gnosis by Lesaffre, maker of LANDKIND Pure Salidroside.
  • Higher clinical dose: 600 mg/day, started one week before and continued during epirubicin chemotherapy (Zhang et al., 2012); no healthy-adult tolerability data exist at this dose.
  • Low-dose complex: 10–20 mg/day salidroside combined with L-malic acid for 6 weeks, with benefit mainly at 20 mg (Nathan et al., 2026); popularized by NutriScience Innovations, maker of SalidroPRO.
  • Whole-extract alternative: SHR-5 rhodiola extract at 340–680 mg/day (Darbinyan et al., 2007), popularized by Alexander Panossian and the Swedish Herbal Institute; such extracts supply only a few milligrams of salidroside.
  • Practitioner extract range: Layne Norton cites 100–600 mg/day of rhodiola extract standardized for salidroside and rosavins (FoundMyFitness).
  • High-extract trial dose: Recent football trials used 2.4 g/day of extract supplying about 12 mg salidroside (NCT07366320).
  • Competing approaches: Pure salidroside offers a defined single molecule; standardized extract adds rosavins and other compounds and has longer trial history. Neither is established as superior.
  • Time of day: First dose on waking and second at least 6 hours later, as in the exercise trial, with a dose about 30 minutes before training (Schwarz et al., 2024).
  • Half-life: No human oral data exist. Intravenous half-life is about 1 hour in rats (Zhang et al., 2013) and 0.5–0.7 hours for a salidroside derivative in humans (Li et al., 2024).
  • Single vs split doses: Twice-daily splitting suits rapid clearance; single doses up to 180 mg were tolerated in a five-person pilot described by Schwarz et al., 2024.
  • Genetic polymorphisms: No pharmacogenetic variant is known to affect dosing; salidroside is mainly kidney-cleared and converted to tyrosol, and any CYP role in its metabolism is unstudied.
  • Sex: No sex-specific dosing exists; a post hoc stress-trial analysis found larger responses in men and non-premenopausal women at the same dose (Nathan et al., 2026).
  • Age: Older adults lack trial data; staying at the studied 60 mg/day (Schwarz et al., 2024) is common practice, especially alongside anticoagulants or diabetes drugs.
  • Baseline biomarkers: No marker guides dose; glucose and clotting baselines matter when interacting medications are used.
  • Pre-existing conditions: Kidney impairment may raise exposure through reduced clearance; hypoxic (low-oxygen) lung disease or altitude may also raise exposure, favoring the lowest studied dose.

Discontinuation & Cycling

  • Duration: Lifelong versus short-term use is undefined; human data cover at most several weeks. The EMA advises against using rhodiola medicines beyond two weeks without medical advice (EMA).
  • Withdrawal effects: None reported for salidroside or rhodiola extracts.
  • Tapering: Not required; salidroside can be stopped abruptly, including 7 days before planned surgery.
  • Cycling: No salidroside data. An extract crossover trial used only 2-week periods, too short to test waning benefit (Darbinyan et al., 2000); hormesis theory (Calabrese et al., 2023) suggests possible tolerance; some practitioners cycle 6–8 weeks on, 1–2 weeks off.

Sourcing and Quality

  • Biosynthetic pure salidroside: Made by fermentation with engineered Escherichia coli (LANDKIND Pure Salidroside, Gnosis by Lesaffre); manufacturer toxicology found no genotoxicity (DNA damage) (Kasprzyk et al., 2022). Nature-identical, without plant contaminants or harvesting pressure.
  • Plant-extracted or chemically synthesized salidroside: Common from bulk suppliers; quality markers are a certificate of analysis confirming identity and high purity by HPLC (high-performance liquid chromatography, a purity test).
  • Rhodiola extracts: The ConsumerLab benchmark is Rhodiola rosea root extract standardized to at least 3% rosavins and/or 1% salidroside; one-fifth of tested products lacked rosavin and some lacked salidroside (Booker et al., 2016).
  • Species substitution: Rhodiola crenulata and other Chinese species contain salidroside but little rosavin; “rhodiola” labels without species or standardization may not match studied products.
  • Third-party testing: USP (United States Pharmacopeia), NSF International or ConsumerLab verification signals tested quality; Informed Sport or NSF Certified for Sport marks matter for drug-tested athletes.
  • Reputable brands: ConsumerLab’s review compared brands including Thorne, Gaia Herbs, Nature’s Way and Solgar (pass/fail results for members); pure-salidroside products typically name LANDKIND as the ingredient.

Practical Considerations

  • Time to effect: The exercise oxygen-uptake effect appeared after three doses over about a day (Schwarz et al., 2024); extract fatigue effects emerged within 2–4 weeks (Darbinyan et al., 2000; Olsson et al., 2009); any longevity effect would take years and is unmeasured.
  • Common pitfalls: Assuming rhodiola extract delivers meaningful salidroside, stacking several adaptogen products, expecting gains in maximal fitness, extrapolating animal lifespan results to humans, and overlooking bleeding interactions.
  • Regulatory status (US): Sold as a dietary supplement; FDA (US Food and Drug Administration) rules make manufacturers responsible for safety before marketing (FDA dietary supplements). In 2020 FDA warned a seller marketing a salidroside product with COVID-19 (coronavirus disease 2019) claims (FDA warning letter).
  • Regulatory status (EU and China): The EMA monograph covers rhodiola root for temporary stress symptoms, not purified salidroside (EMA); China approves rhodiola tablets, capsules and injections (Liang et al., 2024).
  • Cost and accessibility: Pure salidroside and rhodiola extracts are widely sold online and are not exceptionally expensive.

Interaction with Foundational Habits

  • Sleep: Blunting (theoretical). Rhodiola extracts are mildly stimulating, yet SHR-5 improved insomnia scores in depressed patients (Darbinyan et al., 2007). Pure salidroside’s sleep effects are unstudied; morning and early-afternoon dosing, as in the exercise trial, avoids evening stimulation.
  • Nutrition: Indirect. Diet supplies negligible salidroside; in rodents it is absorbed through intestinal glucose transporters (Weng et al., 2026), and effects of taking it with or without food are unstudied. No nutrient depletion is known; olive oil supplies its metabolite tyrosol.
  • Exercise: Potentiating for hard intervals. Pure salidroside improved oxygen use during interval running within days (Schwarz et al., 2024), dosed 30 minutes before testing. Whether its antioxidant actions blunt training adaptations, as high-dose vitamins C and E did (Ristow et al., 2009), is unstudied.
  • Stress management: Potentiating (indirect). SHR-5 extract lowered the morning cortisol (stress hormone) response in burnout patients (Olsson et al., 2009); pure salidroside’s cortisol effect is untested. It complements rather than replaces sleep, breathing practices or meditation.

Monitoring Protocol & Defining Success

Before starting, baseline testing records fasting glucose, HbA1c (glycated hemoglobin, a 3-month blood-sugar average) and serum creatinine, plus INR for anyone taking warfarin. These identify people facing additive glucose lowering, bleeding risk or reduced kidney clearance of salidroside, and give each person a reference for later comparison. Baseline exercise capacity, such as a timed interval session, can also be recorded in the same week.

Ongoing monitoring follows this cadence: INR at 1–2 weeks after starting for warfarin users, fasting glucose at 2 weeks for people on glucose-lowering drugs, then all laboratory markers at 3 months and every 6–12 months during continued use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: additive glucose lowering with diabetes drugs Fast 8–12 hours; draw in the morning; pair with HbA1c
HbA1c 4.0–5.6% (standard reference range) Safety check: tracks average glucose when combined with diabetes drugs HbA1c (glycated hemoglobin, a 3-month average blood sugar); no fasting needed; changes slowly, so recheck at 3 months
INR 0.8–1.2 (standard reference range) Safety check: bleeding risk with warfarin INR (international normalized ratio, a clotting-time test); only for warfarin users, for whom the prescriber’s warfarin target range applies instead; track stability against prior readings
Serum creatinine 0.6–1.3 mg/dL (standard reference range) Safety check: reduced kidney clearance raises salidroside exposure Ranges vary by sex and laboratory; pair with eGFR; avoid heavy meat intake the day before

Qualitative markers of success:

  • Perceived fatigue during demanding work or training
  • Interval-training performance and recovery
  • Sleep quality and onset
  • Mood and stress resilience
  • Bruising, nosebleeds or gum bleeding

Emerging Research

  • Ovarian aging and IVF (in vitro fertilization) (NCT06990685): Open-label phase 2 trial of rhodiola capsules in 370 women aged 35–39; primary outcome ongoing pregnancy; not yet recruiting, completion estimated December 2027. A positive result would add a first human fertility benefit; a null result would weaken the ovarian-aging rationale.
  • Rhodiola in football players (NCT07366320): Placebo-controlled trial in 24 players using 2.4 g/day extract supplying 12 mg salidroside for 4 weeks; primary outcome intermittent running distance; completed October 2025. Published results showed better intermittent running, sprint maintenance and decision-making than placebo (Dou et al., 2026).
  • Caffeine plus rhodiola in soccer (NCT07458594): 96 players tested caffeine, rhodiola extract (about 12 mg salidroside daily) and placebo on jumping performance; completed January 2026. Published results linked rhodiola mainly to lower perceived exertion and maintained heading height (Dou et al., 2026).
  • Independent replication: The only pure-salidroside exercise evidence comes from one manufacturer-supported trial (Schwarz et al., 2024); independent, longer trials in older adults would test whether its oxygen-use and fatigue signals hold.
  • Human pharmacokinetics: No oral human data exist; low oxygen raised exposure in rodents (Weng et al., 2026), and an intravenous salidroside derivative, SHPL-49, completed a first-in-human safety study (Li et al., 2024).
  • Aging mechanisms: HSP90-linked lifespan extension (Zhang et al., 2024), reversal of ovarian blood-vessel aging in mice (Mu et al., 2025) and improved egg quality (Gu et al., 2025) could strengthen the longevity case if replicated in people.
  • Evidence that could weaken the case: Hormesis implies a dose ceiling (Calabrese et al., 2023); an independent rhodiola depression trial was null (Mao et al., 2015); and a COPD meta-analysis reported as pooling salidroside trials actually pooled Danshen (Salvia) polyphenolic acid trials (Wu et al., 2025), leaving no pooled human salidroside data.

Conclusion

Salidroside is a single plant compound, best known as a signature ingredient of golden root and now also sold in pure form made by fermentation. For health-focused adults, its appeal rests on a broad set of laboratory and animal findings: longer life in short-lived animals, protection of brain, liver, kidney and blood vessels, and support for cellular energy and stress defenses. None of these has been tested as a human aging outcome.

Human evidence for the pure compound is thin. One small, short exercise study in young adults suggested slightly better oxygen use during hard intervals without raising peak fitness, and one study in women receiving heart-toxic chemotherapy suggested better-preserved heart-muscle function. A larger study adding malic acid, a fruit acid, suggested less stress and anxiety. Studies of whole-root extracts, which supply far less salidroside, give mixed results for fatigue and low mood.

Short-term use appears well tolerated, with mild complaints at most. The open risks are largely theoretical: added bleeding tendency alongside clot-preventing medication, extra sugar lowering alongside diabetes medication, uncertain effects during cancer treatment, and no information on pregnancy or years of use.

The evidence base carries notable conflicts of interest. The pure ingredient’s safety and exercise studies, and one of its two drug-processing studies, were funded, supplied or co-written by its maker, the stress study by another seller, and the leading extract studies involved the extract’s developers. Overall, salidroside is a biologically active, apparently low-risk compound whose longevity promise currently rests on animal and cell evidence.

Top - Benefits - Risks - Protocol